Viorele 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients who rely on Viorele 28 Day (desogestrel 0.15 mg / ethinyl estradiol 0.02 mg) for contraception are increasingly contacting their providers when they cannot fill their prescriptions. This clinical update summarizes the current availability status, identifies FDA-rated therapeutic equivalents, and provides guidance for prescribers on counseling patients and managing formulary transitions.

Current Availability Status of Viorele 28 Day

As of 2026, Viorele 28 Day is not listed on the FDA Drug Shortages database. Glenmark Pharmaceuticals, Inc. (the manufacturer) continues to produce and distribute this product under ANDA. The NDC for the standard 3-pack carton is 68462-318-29.

Despite the absence of a formal shortage declaration, providers are receiving patient-initiated inquiries about supply difficulties. These likely reflect localized distribution gaps — individual pharmacy stock-outs driven by ordering cycle timing, low-margin inventory decisions, and regional demand fluctuations — rather than a systemic manufacturing or supply failure.

FDA-Rated Therapeutic Equivalents (AB-Rated)

Viorele is a generic formulation of the biphasic desogestrel/ethinyl estradiol regimen (formerly marketed as Mircette). Multiple AB-rated equivalents are available and should be considered when Viorele is unavailable:

Kariva 28 Day (desogestrel 0.15 mg / EE 0.02 mg) — Barr/Duramed

Azurette 28 Day (desogestrel 0.15 mg / EE 0.02 mg) — Glenmark/Aurobindo

Pimtrea 28 Day (desogestrel 0.15 mg / EE 0.02 mg) — Accord Healthcare

Volnea 28 Day (desogestrel 0.15 mg / EE 0.02 mg) — Marlex Pharmaceuticals

Bekyree, Enskyce, Isibloom, Simliya, Kimidess — Additional AB-rated equivalents with the same biphasic desogestrel/EE formulation

All of these contain the same schedule: 21 tablets of desogestrel 0.15 mg / ethinyl estradiol 0.02 mg, followed by 2 inert tablets, then 5 tablets of ethinyl estradiol 0.01 mg. Pharmacists can typically substitute without a new prescription when the prescriber authorizes generic substitution, but a revised prescription allowing substitution by name may prevent patient confusion.

Prescribing Recommendations When Viorele Is Unavailable

When patients present with a prescription for Viorele that cannot be filled locally, consider the following clinical workflow:

Update the e-prescription to specify "desogestrel 0.15 mg / ethinyl estradiol 0.02 mg biphasic 28-day pack — may substitute with Kariva, Azurette, Pimtrea, or Volnea" to give pharmacists maximum dispensing flexibility.

Issue a 90-day prescription and route to a mail-order pharmacy to reduce future interruptions for stable patients.

Counsel patients that the tablet colors differ between equivalent generics (e.g., Kariva uses different color coding than Viorele) but the hormone content is identical. They should take tablets in blister-pack order.

Advise backup contraception if there has been a break in pill-taking during the search for medication. A 7-day backup period is standard following any interruption.

Formulary and Insurance Considerations

Under the Affordable Care Act, most commercial insurance plans are required to cover contraceptives without cost-sharing. Viorele and its AB-rated equivalents are typically covered at Tier 1 or Tier 2. However, insurers may cover some generics and not others within the same class. When switching patients to an equivalent generic:

Advise patients to check their formulary or call member services before transferring the prescription to confirm coverage.

GoodRx or SingleCare coupons may reduce or eliminate out-of-pocket cost when insurance coverage gaps arise — out-of-pocket prices for these generics with coupons can be as low as $9–$31.

Most Medicaid formularies include at least one desogestrel/ethinyl estradiol equivalent, though the specific covered brand may vary by state.

Patient Counseling Points for Providers

When counseling patients who are frustrated by Viorele availability issues, key points to communicate include:

Viorele is not in a national shortage — individual pharmacy stock-outs are common for generic medications and are typically temporary.

Multiple therapeutically equivalent alternatives are available and can be prescribed if needed.

If they are unable to fill locally, medfinder can call multiple pharmacies on their behalf to identify where it is available.

If you'd like to refer your patients to a service that helps them find their medications in stock, visit medfinder for providers.

See also: How to Help Your Patients Find Viorele In Stock: A Provider's Guide.